吉非替尼治疗晚期非小细胞肺癌临床观察

Clinical Observation of Gefitinib Administered for Advanced Non-Small Cell Lung Cancer

目的观察吉非替尼作为二线以上的方案治疗晚期非小细胞肺癌的有效性和安全性。方法本组32例,均经病理学或细胞学检查确诊。其中男18例,女14例,中位年龄62岁,腺癌28例,鳞癌4例,全部患者均接受过2个周期以上的化疗,效果差或不能耐受化疗,均自愿接受吉非替尼单药（250mg/d）治疗。结果32例均可评价疗效和毒副反应。治疗2个月后进行评价,CR1例、PR11例、SD14例、PD6例。RR：37.5%（12/32）,DCR81.25%,TTP3-26个月,中位TTP8个月,MST10个月。结论吉非替尼单药二线以上治疗非小细胞肺癌在东方人、女性、腺癌人群中有效率高,耐受性好,可以有效合理地应用分子靶向药物治疗非小细胞肺癌,有效地发挥治疗肿瘤个体化的优势。

Objective To study the efficiency and safety of gefitinib administered as second-line treatment programs for non-small cell lung cancer. Methods There were 32 cases confirmed by pathology or cytology, among which 18 cases were males and 14 were females. The median age was 62. There were adenocarcinoma 28 cases and squamous cell carcinoma 4 cases. All patients were administered by two cycle chemotherapy, during the treatment the curative effect was poor or patients could not tolerate chemotherapy. 32 cases volunteered for single gefitinib treatment （250 mg/d）. Results 32 cases accepted the efficacy and toxicity evaluation. Evaluation was done after two-month treatment, among all the cases there were CR （ complete remission） 1 case, PR （ partial remission） 11 cases, SD （ stable of disease） 14 cases and PD（progress of disease） 6 cases. RR （response rate） was 37.5% （12/33）. DCR （disease control rate） was 81.25%. TTP （time to progress） was 3-26 months. Median TTP was 8 months and MST was 10 months. Conclusions Gefitinib single treatment as second-line or second-line treatment above for non-small cell lung cancer can get a high efficiency and good tolerability in eastern females and this treatment can be administered as molecular targeting drugs to treat non-small cell lung cancer effectively and reasonably. Gefitinib single treatment can play individual advantages effectively.